3D-QSAR, Molecular Docking and Pharmacokinetic Studies: In-Silico Approach to Search Novel Inhibitors of 5-Alpha Reductase for Treatment of Benign Prostatic Hyperplasia

Q4 Pharmacology, Toxicology and Pharmaceutics
N. Dhingra, Harnoor Kaur, A. Kumari, P. Rana, T. Kaur
{"title":"3D-QSAR, Molecular Docking and Pharmacokinetic Studies: In-Silico Approach to Search Novel Inhibitors of 5-Alpha Reductase for Treatment of Benign Prostatic Hyperplasia","authors":"N. Dhingra, Harnoor Kaur, A. Kumari, P. Rana, T. Kaur","doi":"10.2174/1573408018666220914102231","DOIUrl":null,"url":null,"abstract":"\n\nTo identify novel steroidal 5-alpha reductase (5AR) inhibitors using computational approaches.\n\n\n\nTo exploit the steroidal nuclei for possible modifications by creating a library of 17-oximino-5-androsten-3-carboxamide derivatives and identify potent 5AR inhibitors based on docking and pharmacokinetic parameters.\n\n\n\nBenign prostatic hyperplasia (BPH), is a condition of aged men, that is characterized by lower urinary tract symptoms. Excessive production of dihydrostestosterone (DHT) from testosterone has been found to play a major role in its pathophysiology. Studies targeting the 5AR enzyme have so far resulted in the development of two clinical approved 5AR inhibitors.\n\n\n\nAtom-based three dimensional-quantitative structure activity relationship (3D-QSAR) models have been developed using a selected series of steroidal derivatives as 5AR inhibitors, to elucidate the structural properties required for 5AR inhibitory activities. Further In‒silico studies (molecular docking and pharmacokinetic properties like adsorption, distribution, metabolism, and excretion) of 17-oximino-5-androsten-3-carboxamide derivatives have also been carried out to identify the binding orientation and protein-ligand interactions responsible for the exhibited activity and drug like properties.\n\n\n\nThe best 3D-QSAR model was generated using Partial Least Square method with an excellent correlation coefficient (R², training set) of 0.882, standard deviation (SD) of 0.09, and a predicted coefficient (Q², test set) of 0.814. Docking analysis indicated that the designed series of compounds have comparable binding affinity from -8.961 to -8.017 to the protein and suggested that hydrophobic and electrostatic moieties can have a key role in the inhibition mechanism.\n\n\n\n3D-QSAR, molecular docking and pharmacokinetic studies indicated that 17-oximino-5-androsten-3-carboxamide derivatives could be studied further to provide a new strategy for the treatment of BPH.\n","PeriodicalId":35405,"journal":{"name":"Current Enzyme Inhibition","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Enzyme Inhibition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573408018666220914102231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

To identify novel steroidal 5-alpha reductase (5AR) inhibitors using computational approaches. To exploit the steroidal nuclei for possible modifications by creating a library of 17-oximino-5-androsten-3-carboxamide derivatives and identify potent 5AR inhibitors based on docking and pharmacokinetic parameters. Benign prostatic hyperplasia (BPH), is a condition of aged men, that is characterized by lower urinary tract symptoms. Excessive production of dihydrostestosterone (DHT) from testosterone has been found to play a major role in its pathophysiology. Studies targeting the 5AR enzyme have so far resulted in the development of two clinical approved 5AR inhibitors. Atom-based three dimensional-quantitative structure activity relationship (3D-QSAR) models have been developed using a selected series of steroidal derivatives as 5AR inhibitors, to elucidate the structural properties required for 5AR inhibitory activities. Further In‒silico studies (molecular docking and pharmacokinetic properties like adsorption, distribution, metabolism, and excretion) of 17-oximino-5-androsten-3-carboxamide derivatives have also been carried out to identify the binding orientation and protein-ligand interactions responsible for the exhibited activity and drug like properties. The best 3D-QSAR model was generated using Partial Least Square method with an excellent correlation coefficient (R², training set) of 0.882, standard deviation (SD) of 0.09, and a predicted coefficient (Q², test set) of 0.814. Docking analysis indicated that the designed series of compounds have comparable binding affinity from -8.961 to -8.017 to the protein and suggested that hydrophobic and electrostatic moieties can have a key role in the inhibition mechanism. 3D-QSAR, molecular docking and pharmacokinetic studies indicated that 17-oximino-5-androsten-3-carboxamide derivatives could be studied further to provide a new strategy for the treatment of BPH.
3D-QSAR,分子对接和药代动力学研究:寻找新型5- α还原酶抑制剂治疗良性前列腺增生的计算机方法
使用计算方法鉴定新型甾体5-α还原酶(5AR)抑制剂。通过建立17-羟基氨基-5-雄烯-3-羧酰胺衍生物库,利用甾体核进行可能的修饰,并基于对接和药代动力学参数鉴定强效5AR抑制剂。良性前列腺增生(BPH)是老年男性的一种疾病,其特征是下尿路症状。睾酮过量产生二氢睾酮(DHT)在其病理生理学中起着重要作用。到目前为止,针对5AR酶的研究已经开发出两种临床批准的5AR抑制剂。使用一系列选定的甾体衍生物作为5AR抑制剂,开发了基于原子的三维定量结构-活性关系(3D-QSAR)模型,以阐明5AR抑制活性所需的结构特性。还对17-氧基氨基-5-雄烯-3-甲酰胺衍生物进行了进一步的计算机研究(分子对接和药代动力学特性,如吸附、分布、代谢和排泄),以确定导致表现出的活性和类药物特性的结合方向和蛋白质-配体相互作用。使用偏最小二乘法生成了最佳的3D-QSAR模型,相关系数(R²,训练集)为0.882,标准差(SD)为0.09,预测系数(Q²,测试集)为0.8 14。对接分析表明,所设计的一系列化合物对蛋白质的结合亲和力在-8.961至-8.017之间,分子对接和药代动力学研究表明,17-羟基氨基-5-雄烯-3-甲酰胺衍生物可以进一步研究,为BPH的治疗提供新的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Enzyme Inhibition
Current Enzyme Inhibition Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
CiteScore
1.30
自引率
0.00%
发文量
30
期刊介绍: Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信